Get the Stockscreener App
62.37
0.68%
-0.43
After Hours:
62.37
Dexcom Inc stock is traded at $62.37, with a volume of 3.53M.
It is down -0.68% in the last 24 hours and down -15.06% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$62.80
Open:
$62.8
24h Volume:
3.53M
Relative Volume:
0.73
Market Cap:
$24.00B
Revenue:
$4.66B
Net Income/Loss:
$836.30M
P/E Ratio:
29.80
EPS:
2.093
Net Cash Flow:
$1.08B
1W Performance:
-6.69%
1M Performance:
-15.06%
6M Performance:
-5.61%
1Y Performance:
-7.35%
1-Day Range:
$61.91
$63.66
1-Week Range:
$61.62
$67.93
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
62.37 | 24.17B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
102.38 | 178.41B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
329.40 | 125.84B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.06 | 111.25B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.00 | 93.26B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.26 | 46.17B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
BNY Mellon Large Cap Securities Fund, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
Pallas Capital Advisors LLC Decreases Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. Experiences Revision in Stock Evaluation Amid Market Pressures - Markets Mojo
DexCom Inc. stock rises Tuesday, still underperforms market - MarketWatch
Soleus Capital Management, L.P.'s DexCom Inc(DXCM) Holding History - GuruFocus
DexCom Stock Hits Day Low of $62 Amid Price Pressure - Markets Mojo
DexCom Inc (DXCM) Stock Price Down 5.81% on Mar 30 - GuruFocus
DexCom, Inc. $DXCM Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Dexcom Inc. Stock: Leader in Continuous Glucose Monitoring Faces Evolving Diabetes Care Landscape - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - MSN
DAVENPORT & Co LLC Reduces Stake in DexCom, Inc. - National Today
DAVENPORT & Co LLC Has $1.87 Million Position in DexCom, Inc. $DXCM - MarketBeat
DXCM (DexCom) Earnings Power Value (EPV) : $11.42 (As of Dec25) - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know - Yahoo Finance UK
DXCM Technical Analysis | Trend, Signals & Chart Patterns | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DEXCOM YoY EBITDA Growth: 52.52% | Significantly Undervalued - GuruFocus
Vanguard (DXCM) amendment shows 0 shares after internal realignment - Stock Titan
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
DXCM (DexCom) Payments of Debt : $0 Mil (TTM As of Dec. 2025) - GuruFocus
DEXCOM EBIT per Share: $2.73 | Significantly Undervalued - GuruFocus
2026-03-26 | DexCom, Inc. (DXCM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:DXCM | Press Release - Stockhouse
Dexcom Inc. stock surges on Evercore ISI upgrade to Outperform amid CGM market expansion - AD HOC NEWS
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom Inc (NASDAQ:DXCM) Presents a Growth Stock Breakout Opportunity - ChartMill
Nordea Investment Management AB Acquires 137,986 Shares of DexCom, Inc. $DXCM - MarketBeat
Assenagon Asset Management S.A. Increases Position in DexCom, Inc. $DXCM - MarketBeat
Dexcom Edges Up on Institutional Buying as CGM Leader Trails $260M Volume Ranks 465th - Bitget
Dexcom Inc. stock rises on Evercore ISI upgrade to Outperform with $90 target amid CGM market moment - AD HOC NEWS
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom Inc. stock faces spotlight amid continuous glucose monitoring sector evolution and governance - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - ACCESS Newswire
DexCom (NASDAQ:DXCM) Upgraded to "Outperform" at Evercore - MarketBeat
Evercore ISI upgrades DexCom stock rating on growth outlook - Investing.com
DXCM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
E. Ohman J or Asset Management AB Has $7.67 Million Stock Position in DexCom, Inc. $DXCM - MarketBeat
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
DexCom, Inc. $DXCM Shares Acquired by Gradient Investments LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Devon Energy Corp stock eyes dividend surge amid Coterra merger push and rising oil prices - ad-hoc-news.de
Union Bancaire Privee UBP SA Increases Stake in DexCom - National Today
Union Bancaire Privee UBP SA Has $1.41 Million Stake in DexCom, Inc. $DXCM - MarketBeat
Mizuho raises DexCom (DXCM) price target to $90 from $78 after earnings beat - MSN
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Stockholders to Reach Out - ACCESS Newswire
Dexcom stock falls despite Q4 earnings beat, G7 rollout drives growth - MSN
Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 1,700 Shares of Stock - MarketBeat
Dexcom (DXCM) legal chief sells 1,700 shares in 10b5-1 trade - Stock Titan
Mizuho Markets Cayman LP Acquires 53,093 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):